Skip to main content

Table 2 Unadjusted incidence rates and cumulative incidence of events in patients newly treated with antifibrotic drugs

From: Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis

 

Unadjusted incidence rate

[95% CI] (per 100 person-years)

One-year cumulative incidence of event, % [95% CI]

Three-year cumulative incidence of event, % [95% CI]

All-cause mortality

Patients initiating pirfenidone

10.91 [8.81–13.51]

9.79 [7.41–12.56]

25.46 [19.60–31.71]

Patients initiating nintedanib

15.36 [12.13–19.44]

14.25 [10.81–18.14]

31.11 [21.16–41.56]

Acute respiratory-related hospital admissions

Patients initiating pirfenidone

26.99 [23.34–31.21]

22.85 [19.35–26.52]

48.26 [39.76–56.24]

Patients initiating nintedanib

30.70 [25.69–36.68]

27.46 [22.95–32.14]

43.62 [30.75–55.79]

Treatment discontinuation

Patients initiating pirfenidone

82.88 [75.27–91.26]

53.75 [50.13–57.22]

Patients initiating nintedanib

64.82 [56.85–73.91]

46.53 [41.96–50.97]

  1. CI confidence interval